Summary: The European competent authorities for medicinal products have
just
approved ALK's new adrenaline pen, JEXT®, for emergency treatment of
severe
acute allergic reactions. In the months ahead, ALK expects to launch
JEXT® on
the first European markets as a substitute for the company's
existing
inlicensed product. 
 
As announced on 7 October 2010, ALK has
developed a new and improved adrenaline
auto-injector called JEXT®. The
competent authorities for medicinal products in
17 European countries have
just approved JEXT® for the emergency treatment of
severe acute allergic
reactions (anaphylaxis) caused by, for example, foods or
bee stings. The
approval has been obtained by means of the European
authorities' Decentralised
Procedure. Following this approval, the national
authorities will issue formal
marketing authorisations. This is expected to
happen in the near future.


JEXT® is expected to be available on the first European markets on 1
January
2011. ALK holds the global product rights and is planning to expand
its
geographical presence with adrenaline products considerably. Furthermore,
with
the introduction of JEXT®, ALK expects to improve the company's gross
margin
and substantially improve earnings from the business area within the
next few
years. 

ALK-Abelló A/S


Jens Bager
President and
CEO


Contact: Jens Bager, President and CEO, tel. (+45) 4574
7576

Investor Relations: Per Plotnikof, tel. (+45) 4574 7527, mobile (+45)
2261 2525
Press: Martin Barlebo, tel. (+45) 4574 7901, mobile (+45) 2064
1143